Change in Sweat Chloride as a Clinical End Point in Cystic Fibrosis Clinical Trials

A CFTR Potentiator in Patients with Cystic Fibrosis and the <i>G551D</i> Mutation

Bonnie W. Ramsey, Jane C. Davies, Noel G. McElvaney et al. · New England Journal of Medicine · 2011 · 2.2K citations · Full text

Medicine, Molecular Biology, Molecular Genetics +8

Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus Report

Philip M. Farrell, Beryl J. Rosenstein, Terry B. White et al. · The Journal of Pediatrics · 2008 · 1.1K citations · Full text

Medicine, Child Health, Pediatrics +9

Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- <i>CFTR</i> Mutation

Frank J. Accurso, Steven M. Rowe, John P. Clancy et al. · New England Journal of Medicine · 2010 · 802 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

ABNORMAL ELECTROLYTE COMPOSITION OF SWEAT IN CYSTIC FIBROSIS OF THE PANCREAS

Paul A. di Sant'Agnese, R. Clement Darling, George A. Perera et al. · PEDIATRICS · 1953 · 522 citations

Medicine, Endocrinology, Physiology +17

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation

John P. Clancy, Steven M. Rowe, Frank J. Accurso et al. · Thorax · 2011 · 496 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16